Objective: This study aims to examine the relationship between serum levels of endocannabinoids and the metabolic profile in patients diagnosed with Polycystic Ovary Syndrome (PCOS). Methods: A quantitative, prospective, cross-sectional analytical study was conducted, involving female patients aged 18 to 45 with a confirmed diagnosis of PCOS. The sample was selected using simple random probabilistic sampling, and the sample size was determined using a formula with a 95% confidence level, 6% precision, and a variance (s2) of 800. Biochemical variables were assessed through blood sample analysis. Results: Among the 50 participants, 26 (52%) were classified as obese, 11 (22%) as overweight, and 13 (26%) as having a normal weight. HOMA-IR calculations indicated that 24 participants (48%) exhibited insulin resistance. Spearman's correlation test revealed no significant relationship between the serum levels of endocannabinoids and the patients' metabolic profiles, including anandamide (HOMA-IR [-0.08], glucose [-0.17], cholesterol [0.07], triglycerides [-0.06], BMI [-0.12]), and 2-arachidonoylglycerol (HOMA-IR [-0.03], glucose [-0.12], cholesterol [0.14], triglycerides [-0.04], BMI [-0.1]). Conclusions: This study concludes that there is no discernible association between serum endocannabinoid levels and the metabolic profiles of patients with PCOS attending UMF No. 53 and 47 at IMSS.Objetivo: Analizar la relación que existe entre los niveles séricos de endocannabinoides y perfil metabólico en pacientes con diagnóstico de SOP. Métodos: Se realizó un estudio cuantitativo, prospectivo, transversal analítico, se incluyeron pacientes con diagnóstico de SOP de 18 a 45 años. La muestra se realizó mediante muestreo probabilístico aleatorio simple y el cálculo con la fórmula para estimar una media con un nivel de confianza del 95%, precisión del 6%, varianza (s2) de 800. Mediante toma de muestra sanguínea se determinaron variables bioquímicas. Resultados: De las 50 mujeres estudiadas, 26(52%) tienen obesidad, 11(22%) sobrepeso y 13(26%) peso normal. Se calculó HOMA-IR, encontramos 24(48%) con resistencia a la insulina. Mediante prueba de correlación de Spearman se observó que no existe relación entre los niveles séricos de endocannabinoides y el perfil metabólico de las pacientes, tanto para anandamida (HOMA-IR[-0.08], glucosa[-0.17], colesterol[0.07], triglicéridos[-0.06], IMC[-0.12]), como para 2-araquinoidil glicerol (HOMA-IR[-0.03], glucosa[-0.12], colesterol[0.14], triglicéridos[-0.04], IMC[-0.1]). Conclusiones: No existe una relación entre los valores séricos de endocannabinoides y perfil metabólico en pacientes con SOP en las UMF No. 53 y 47 del IMSS.